Target Product Profiles for Drug-Drug and Drug-Device MPT Products. Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network
|
|
- Lauren Garrison
- 5 years ago
- Views:
Transcription
1 Target Product Profiles for Drug-Drug and Drug-Device MPT Products Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network November 3, 2011
2 Genesis of the Drug-Drug/Drug Device Working Group May 5, 2011 Think Tank USAID, CAMI, AVAC Think Tank Description of a TPP: How a proposed candidate product addresses critical attributes Outline framework for development via target specification range Why a TPP? To define attributes/parameters for MPT products with highest potential public health impact (i.e., prioritization) To Guide donor investment and sponsor development strategies Two working groups formed Drug-Drug/Drug Device Vaccines
3 Drug-Drug/Drug Device Working Group: P. Harrison (IC), M. Kerrigan (BMGF), J. Manning (USAID), J. Marrazzo (U Wash/MTN), J. Romano (NWJ/MTN), J. Turpin (NIAID/DAIDS) Development Strategies Product/ Technology Survey MPT TPP Beyond the Scope of the Initial Phase of this Effort Primary Deliverable: 1 st Pass: Critical Attributes and Appropriate Parameter Ranges for High Impact MPT Products to be Challenged by the Field* *Conceived as a first step in defining relevant MPT TPP
4 Initial TPP Development Process and Format: Critical Product Attributes and Parameter Ranges Critical Attribute Minimally Acceptable Preferred Critical Attribute Minimally Acceptable Preferred Indications Adherence Target Population Time to Market Administration Route R&D Costs Product Presentation Reversibility Dosage Form & Schedule Side Effects Efficacy IP Status Storage Conditions Access Potential Shelf Life Other Health Benefits Cost Packaging Disposal/Waste Contra-indications, warnings, precautions, use by preg/lact women
5 Can a Single TPP for Drug-Drug or Drug-Device MPT Products Be Built? Non- HC Anti- Microbial HC Pro-Biotic Anti- Viral Barrier Anti- Fungal HIV Chlamydia BV HSV Pregnancy Gonorrhea Candida HPV Syphilis Trichomonas Vaginal Film Vaginal Tablets Topical Daily Topical Peri-Coital Oral Tablet Vaginal Ring Non-IVR Device Vaginal Gel Systemic Sustained Topical Sustained Injectable Implantable Oral Daily Oral Peri- Coital
6 Working Group Approach: Address General Concepts (not specific product configurations) Build/populate alternative tables based on general product concepts (n=5) Other Survey Input Solicit expert review and comment (n= 8-14, R&D/provider/ user experts) Consolidate consensus views around concepts; capture outlier positions Report results for the next round of review
7 Table 1: Prioritization of Multipurpose Prevention Technology Indications Indication Description Magnitude of priority; public health impact in target populations; definition of most relevant target populations; other HIV Prevention/ Contraception HIV/STI Prevention STI Prevention/ Contraception Single product preventing HIV transmission/ pregnancy Single product preventing HIV/STI transmission Single product preventing STI transmission/ pregnancy Highest Priority: Highest potential for impact to prevent both pregnancy and HIV in low resource settings Medium Priority, determined largely by the specific STI, and relevance to HIV transmission Medium priority, determined largely by the specific STI, and consequent disease burden for women
8 Table 2: Prioritization of STI Indications for MPT Product Development Target STI in MPT Proposed Priority Rationale HSV Very High High Incidence, HIV co-factor HPV Very High High incidence, burden of disease BV High Incidence, potential enhancement of HIV infection Chlamydia Moderate Incidence, disease burden syndromic management potential Trichomonas Moderate Incidence, disease burden, syndromic management potential Gonorrhea Low Incidence, disease burden Syphilis Low Incidence, disease burden
9 Tables 1 and 2: Consensus Responses HIV/Contraception slightly higher priority than HIV/STI STI/Contraception not a priority HSV: high priority given role in HIV infection, feasibility prospects, and marketing potential worldwide HPV: moderate to high priority given oncogenic potential Seen addressable via vaccine; availability needs to be increased Possible MPT product to cover all HPV types and bridge gap to vaccine availability BV: high priority given relevance of vaginal health to HIV and other infections
10 Tables 1 and 2: Consensus Responses (continued) Chlamydia: moderate priority given high prevalence in certain settings; high disease burden potential Curable with cheap antibiotic course Age specific screening and treatment is effective Trichomoniasis: moderate priority given high disease burden, induced inflammation and enhanced HIV shedding Product feasibility challenges recognized for prevention Gonorrhea and Syphilis: low priority Prevalence and curability cited Key factors: Relevance to HIV; technical feasibility; prevalence; treatability; public health burden
11 Table 3: Routes of Administration and Dosage Forms Route of Administration Topical: Daily Dosage Form(s) Gels, tablets films, etc. Development Priority 2.1 Adherence Potential 3.0 Topical: Peri-coital Gels, tablets, films, etc Sustained Release Device Injectable Implantable Oral: Daily IVR, barrier device with drug release Single product/ Dual indication Single product/ Dual indication Single pill/ Dual Indication Oral: Peri-coital Single pill/ dual indication Scale: 1= highest priority/potential; 3= lowest priority/potential
12 Tables 3: Consensus Responses Adherence! Vaginal rings: Highest development priority/highest adherence potential Technical feasibility high; cheap; proven contraception technology Use in menses? User removal? Peri-coital products were higher priority than daily products Adherence burden too high for daily Peri-coital cheaper than daily Peri-coital must be fast acting; technical challenge Component elements for oral daily are available; technically feasible Topical products were higher priority than oral products Topical contraceptives have technical challenges
13 Tables 3: Consensus Responses (Continued) Injectable: High adherence potential (pending dosing interval) Reversibility issues Long term systemic exposure concerns Technically challenging Skilled provider? Implantable: High adherence potential Technically challenging/low feasibility More reversible than injectable Potentially low uptake in target populations; skilled provider required Other key points: No mention of HC issue and dosage form linkage Efficacy cited as relevant to dosage form preference Side effects via systemic exposure repeatedly cited Peri-coital definition ranged from +/- 30 min to +/- 24 hr
14 Survey of ARHP Members: Tables 1, 2 & 3 Issues Informally conducted by J. Manning (USAID) ; n= 593 Which of the following combinations of prevention options would be your highest priority for development? Unintended pregnancy & HIV % HIV & other STIs % Unintended pregnancy & other STIs % Preventing which of the following STIs is your highest priority? HIV/AIDS % HSV (Herpes Simplex Virus) % HPV (Human Papillomavirus) % BV (Bacterial Vaginosis) %
15 Survey of ARHP Members: Tables 1, 2 & 3 Issues Which of the following modes of administration for a comb. product would be most accepted and used by your clients? Topical pericoital (eg: gel, film, or tablet used 8 hrs % before or after sex) Oral (daily or pericoital) % Sustained release device (eg: vaginal ring used % continuously for 3 mos) Injection % Implant % IUD % USA Contraception & STI Oral Dosage Form HPV > HSV Domestic vs. SSA, SEA, Etc. SSA, SEA, Etc. HIV & Contraception/HIV & STI Sustained Release Device HSV > HPV Effect on Pharma Involvement?
16 Table 4: Product Attributes & Parameters Parameter Range Dosage Forms Topical Sustained Injectable Implantable Oral Release Shelf Life Min 24 mos 24 mos 24 mos 24 mos 24 mos Pref >36 mos >36 mos >36 mos > 36 mos >36 mos Storage Conditions Min o C/65% RH o C/65% RH 4 o C 4 o C o C/65% RH Pref >30 o C/75% RH >30 o C/75% RH >30 o C/75% RH 40 o C/75% RH o C/75% RH Schedule/ Dosing Min Daily or Pericoital Monthly 2 mos 3 mos Daily or Pericoital Regimen Pref +/-24 hr of sex Yearly 12 mos >12 mos +/- 24 hr of sex Infrastructure Needs Min Clinic w/medical support Clinic w/medical support Clinic w/medical support Clinic w/ medical support Clinic w/medical support Pref Local Healthcare Provider Local Healthcare Provider Local Healthcare Provider Clinic w/ medical support Local Healthcare Provider
17 Table 4: Product Attributes & Parameters (Continued) Parameter Range Dosage Forms Topical Sustained Injectable Implantable Oral Release Provision Min Clinic/User Clinic/User Clinic/Phys Clinic/Physician Clinic/User Source and Administration Pref Reversibility timing Local Healthcare Provider or Pharmacy/User Packaging Min Controlled disposal Local Healthcare Provider or Pharmacy/User Trained Healthcare Provider Trained Healthcare Provider Local Healthcare Provider or Pharmacy/User Min 14 days 30 days 90 days 90 days 14 days Pref Immediate <24 hours 14 days?? Feasible? 14 Days?? Feasible? <24 hours Controlled Controlled disposal disposal Pref Concealable, user disposal Concealable, user disposal With all necessary materials for administration With all necessary materials for administration??? Biodegradable? Removable? Concealable, user disposal
18 Table 4: Consensus Summary Generally accepting of parameters as posed All attributes considered high priority except: Reversibility timing (medium) and packaging (low)- no consensus Strong preference for 40 o C storage temp 4 o C seen as potentially not feasible Preference for 36 month shelf life Resupply issues, access to testing/monitoring, cold chain storage needs all cited as relevant Concerns re: Packaging (sterility) and storage (temperature) for injectable and implantable Dosing interval also of concern
19 Table 4: Consensus Summary (continued) Potential for local uptake and support of specific product dosage forms in specific settings was raised Level of healthcare provider expertise and involvement Monica s Challenge Do the access strategies and product education activities need to change to support the development of effective products that traditionally did not achieve high uptake due to the dosage form?
20 Table 5: General Issues Parameter Minimally Acceptable Preferred Target Efficacy HIV 40%-70% pending product >80% type/indication Contraception Current levels w/ recommended use >current levels per contraceptive form STI 40% >80% Side Effects Contraindications, warnings, use w/ pregnancy, etc OTC with no pregnancy or major systems warnings or contraindication with other vaginal products Time to licensure 8-12 years 5 years R&D costs <$400M <$150M Yearly MPT product cost per user <$100/year <$50/year
21 Tables 5: Consensus Summary HIV Efficacy: Minimally acceptable %; Typical use- 60%; Perfect use >80% Contraception Efficacy: Current levels with recommended use Efficacy-STI: Minimally acceptable %; no comments on posed >80% preferred target Side Effect Issues: Acceptable to most women and generally no worse than comparable single use products No effects on daily activities Difficult to answer in the absence of other details (e.g., product efficacy) Continued concerns expressed regarding systemic exposure/resistance
22 Tables 5: Consensus Summary (continued) Contraindications, Warnings, Use with Pregnancy: Equal standards for drugs and devices in the developed world General concerns about ARV during pregnancy and breast feeding Different recommendations for Rx vs OTC products Time line to licensure: 5 years preferred; 8-12 years minimally acceptable R&D Costs: No comments provided Preferred Costs: $12-40/year
23 Summary Findings from the TPP Survey for Drug-Drug and Drug-Device MPT Products Priority Indications: HIV/Contraception followed closely by HIV/HSV Other STI with contraception not a priority Dosage Forms Major determining factor is PRODUCT ADHERENCE Highest development priority: Vaginal Rings Key Attributes and Parameters: Shelf life: 36 months Storage temperature: 40 o C Other attributes are all in the context of safety, efficacy, and each other!
24 Summary Findings from the TPP Survey for Drug-Drug and Drug-Device MPT Products Efficacy Targets: HIV: 40-80% Contraception: Current levels with recommended use STI: at least 40% Side Effects: No worse than individual indication products Needs evaluation in the context of acceptability and efficacy No significant input on cost of R&D, time to market, user costs, IP Results can vary depending on who is asked
25 Conclusions of the TPP Survey Exercise Defining broadly applicable attributes and parameters for all drug-drug or drug-device MPT products is challenging The interplay of different attributes is complex and unique per product concept and design It is possible to create general development priorities and fundamental design targets for such MPT products Useful to funders in terms of investment prioritization Useful to developers in terms of R&D focus
26 Outstanding Issues/Questions/Challenges Regarding Drug-Drug or Drug-Device MPT Products Expanded level of input Evaluate specific product concepts against key attributes and parameters of the (evolving) TPP Incite/manage collaborative funding and development efforts to achieve maximum efficiency Pursue the developed world potential of MPT products Build high impact MPT products and achieve the necessary access of such products to target populations
Target Product Profiles for Drug-Drug and Drug-Device MPT Products
Target Product Profiles for Drug-Drug and Drug-Device MPT Products Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network January 10, 2012 Genesis of the Drug-Drug/Drug Device Working Group May 5,
More informationWhat do women want? EMERGING TECHNOLOGIES IN REPRODUCTIVE HEALTH PANEL DISCUSSION
What do women want? EMERGING TECHNOLOGIES IN REPRODUCTIVE HEALTH PANEL DISCUSSION PANELISTS: SAUMYA RAMARAO SABRINA JOHNSON NOMITA CHANDHIOK BEATRICE MUTALI POPULATION COUNCIL WOMANCARE GLOBAL INDIAN COUNCIL
More informationMultipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health
Multipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health Session Objectives This session is designed to help you: Define multipurpose prevention technologies (MPTs) Describe 3 benefits
More informationPart 1. What are MPTs & why do we need them?
Faculty Disclosures Multipurpose Prevention Technologies (MPTs): The Intersection of Contraceptives, HIV & STDs Dr. Young Holt has no disclosures Bethany Young Holt, PhD MPH CAMI/Public Health Institute
More informationSupporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings
Supporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings Judy Manning, PhD Office of Population & Reproductive
More informationMULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) FOR SEXUAL AND REPRODUCTIVE HEALTH
MULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) FOR SEXUAL AND REPRODUCTIVE HEALTH Bethany Young Holt, PhD MPH Executive Director, CAMI Reproductive Health 2013 21 September 2013 Denver, CO Session Objectives
More informationReview Article Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy
AIDS Research and Treatment Volume 2013, Article ID 790154, 15 pages http://dx.doi.org/10.1155/2013/790154 Review Article Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy
More informationTable for Identifying Knowledge Gaps for Use in the World Report on Knowledge for Better Health
Table for Identifying Knowledge Gaps for Use in the World Report on Knowledge for Better Health Types of knowledge needed Maternal and Newborn Health Family Planning Unsafe abortion RTI/STIs New knowledge
More informationSTI vaccines are a major priority for sustainable global STI control. Large number of infections globally
Brisbane, 4 Sept 05 STI are a major priority for sustainable global STI control Preliminary WHO estimates: 357 million new cases of curable STIs in 0 The global roadmap for STI : Moving forward Large number
More informationLooking at NY: Our rate of chlamydia is higher than the US as a whole; we rank 13th among all states.
1 In this presentation, we will discuss: What are the most common STDs in NYS What are the most common STDs Can I get gonorrhea from oral sex How do you know if you/or your partner has an STD? Does getting
More informationMultipurpose prevention technologies (MPTs): a promising response to current challenges around hormonal contraceptive methods and HIV
Multipurpose prevention technologies (MPTs): a promising response to current challenges around hormonal contraceptive methods and HIV 27 January 2016 10:30-11:50 AM Kintamani 1 2016 International Conference
More informationRon Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationContraception for Women and Couples with HIV. Knowledge Test
Contraception for Women and Couples with HIV Knowledge Test Instructions: For each question below, check/tick all responses that apply. 1. Which statements accurately describe the impact of HIV/AIDS in
More informationToward global prevention of sexually transmitted infections: the need for STI vaccines
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS Toward global prevention of sexually transmitted infections: the need for STI vaccines
More informationWhy Condoms Still Matter. Bidia Deperthes Sr HIV Prevention Advisor- AIDS 2018 Amsterdam
Why Condoms Still Matter Bidia Deperthes Sr HIV Prevention Advisor- UNFPA @ AIDS 2018 Amsterdam 1 Condoms: Multipurpose Devices Male and female condoms are the only barrier methods that simultaneously
More informationMTN 2011 Annual Meeting Arlington, VA. The Microbicide Pipeline: A Critical Review. J. Romano March 29, 2011
MTN 2011 Annual Meeting Arlington, VA The Microbicide Pipeline: A Critical Review J. Romano March 29, 2011 What is the microbicide pipeline and how is it prioritized and progressed? The Microbicide Pipeline?
More informationLTASEX.INFO STI SUMMARY SHEETS FOR EDUCATIONAL USE ONLY. COMMERCIAL USE RIGHTS RESERVED. COPYRIGHT 2013, JEROME STUART NICHOLS
LTASEX.INFO STI SUMMARY SHEETS FOR EDUCATIONAL USE ONLY. COMMERCIAL USE RIGHTS RESERVED. COPYRIGHT 2013, JEROME STUART NICHOLS LTASEX.INFO! IN AIDS is a treatable complication of advanced HIV infection.
More informationtransmission (MTCT) of
Training Course in Sexual and Reproductive Health Research 2013 Module: Principles and Practice of Sexually Transmitted Infections Prevention and Care Dual elimination of mother-to-child transmission (MTCT)
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More information9p1 Identify the factors that contribute to positive relationships with others. 9p6 Describe the factors that lead to responsible sexual relationships
Lesson Eight Title: Theme: Time: Materials: Wrapping up the Sexual Health Unit The 60 minutes * Sexuality Review-Quiz * Sexuality Review-Answer Sheet * Sexual Q & A -Laminated Game Cards * Sexual Q & A
More informationPresentation Overview
Effectiveness of female condoms in the prevention of pregnancy and sexually transmitted infections Bidia Deperthes Technical Advisor Condom Programming United Nations Population Fund Theresa Hatzell Hoke
More informationFactors Affecting Dose Selection
Long Acting Injectables for HIV-PrEP Factors Affecting Dose Selection June 14 to 16, 2017 Mark Milad Milad Pharmaceutical Consulting, LLC Consultant to the Bill and Melinda Gates Foundation Outline Challenges
More informationHIV-1 and STDs in a rapidly transforming China challenges to disease prevention
HIV-1 and STDs in a rapidly transforming China challenges to disease prevention A l l e n Z. W u N a n j i n g U n i v e r s i t y E x p l o r i n g C o m m o n a l i t i e s i n G l o b a l H e a l t
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationOutline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012
HIV and Other Sexually Transmitted Infections Tanya Kowalczyk Mullins, MD, MS Division of Adolescent Medicine Cincinnati Children s Hospital Medical Center Outline Epidemiology of select STIs and HIV STIs
More informationInitiative for Multipurpose Prevention Technologies (IMPT) mission IMPT
The Initiative for Multipurpose Prevention Technologies (IMPT) for sexual and reproductive health was established in the spring of 2009 to unite reproductive health researchers, health care providers,
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationSexually Transmi/ed Diseases
Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More information1.Abstinence no sex (Abstinence only education has been proven ineffective in preventing unwanted pregnancies)
REPRODUCTIVE SYSTEM Objectives: 1. Contraception 2. STDs 1. Ovary Transplants 2. Freezing Eggs 3. Choosing Gender 4. The Male Pill, parts 1&2 5. Male Birth Control: RISUG 6. Birth Control. 1.Abstinence
More informationAFR/RC67/7 13 June 2017
13 June 2017 REGIONAL COMMITTEE FOR AFRICA Sixty-seventh session Victoria Falls, Republic of Zimbabwe, 28 August 1 September 2017 ORIGINAL: ENGLISH Provisional agenda item 10 GLOBAL HEALTH SECTOR STRATEGY
More informationPopulation attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,
Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia, 1994-2012 10 th International Workshop on HIV Transmission Kristin M. Wall, PhD kmwall@emory.edu
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationThe contents are the responsibility of CAMI/Public Health Institute and do not necessarily reflect the
The Wellcome Trust, which hosted this Forum, is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health through supporting the brightest minds in biomedical
More informationSexually Transmitted
CHAPTER 22 Infections, Including HIV Key Points for Providers and Clients People with sexually transmitted infections (STIs), including HIV, can use most family planning methods safely and effectively.
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationAcidform Vaginal Gel Contraception and STI Prevention
Acidform Vaginal Gel Contraception and STI Prevention Empower Women. Change the World. David R. Friend, PhD Sr VP, R & D 1 Acidform Gel Acidform is a viscous, acidic (ph 3.5) gel with a high buffering
More informationSTI Prevention: Housekeeping and How We Use Public Health. M. Terry Hogan, MPH Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012
Sexual and Reproductive Health and HIV Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Global estimates of HIV-(2009) People living with HIV 33.3 million [31.4 35.3
More informationWelcome and State of the Network. Cape Town, South Africa 27 th September 2016
Welcome and State of the Network Cape Town, South Africa 27 th September 2016 The HIV/AIDS Epidemic in 2016 17 million people were accessing antiretroviral therapy 36.7 million people globally were living
More informationIndex. Infect Dis Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Infect Dis Clin N Am 19 (2005) 563 568 Index Note: Page numbers of article titles are in boldface type. A Abstinence in genital herpes management, 436 Abuse sexual childhood sexual behavior effects of,
More informationProduct Development for Vaccines Advisory Committee:
Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee
More informationSTIs- REVISION. Prof A A Hoosen
STIs- REVISION Prof A A Hoosen Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria and the NHLS Microbiology Tertiary Laboratory at the Pretoria Academic Hospital Complex
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV
More informationThe Impact of Sexually Transmitted Diseases(STD) on Women
The Impact of Sexually Transmitted Diseases(STD) on Women GAL Community Symposium AUM September 2, 2011 Agnes Oberkor, MPH, MSN, CRNP, Nurse Practitioner Senior Alabama Department of Public Health STD
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationPractice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -
ASK SCREEN Test for HIV and STI Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically - Routinely obtain a thorough sexual history from all
More informationSexually Transmissible Infections (STI) and Blood-borne Viruses (BBV) A guide for health promotion workers
Sexually Transmissible Infections (STI) and Blood-borne Viruses (BBV) A guide for health promotion workers Sexual & Reproductive Health Western Australia Chlamydia (bacterial infection) Unprotected vaginal
More informationPROGRESS REPORT OF THE IMPLEMENTATION OF THE GLOBAL STRATEGY FOR PREVENTION AND CONTROL OF SEXUALLY TRANSMITTED INFECTIONS:
PROGRESS REPORT OF THE IMPLEMENTATION OF THE GLOBAL STRATEGY FOR PREVENTION AND CONTROL OF SEXUALLY TRANSMITTED INFECTIONS: 2006 2015 Document for the World Health Assembly 27 April 2015 ii Contents Acronyms
More information½ of all new infections are among people aged although this age group represents <25% of the sexually experienced population.
Impact Almost 20 million - newly diagnosed STD s/sti s each year. $16 billion cost of treating STI s ½ of all new infections are among people aged 15-24 although this age group represents
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationFAMILY PLANNING AND SEXUALLY TRANSMITTED INFECTIONS INCLUDING HIV. Unit 20. Learning Objectives. Teaching Resources in this Unit
Unit 20 FAMILY PLANNING AND SEXUALLY TRANSMITTED INFECTIONS INCLUDING HIV Learning Objectives By the end of this unit, learners will be able to: Define sexually transmitted infections (STIs) Outline groups
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationA Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation
More informationSeveral of the most common STDs are often asymptomatic. Asymptomatic
What Are STDs? Several of the most common STDs are often asymptomatic. Asymptomatic Individuals show no symptoms, or the symptoms are mild and disappear after the onset of the infection Common STDs There
More informationThe case for Multipurpose Prevention Technologies
The case for Multipurpose Prevention Technologies Professor Helen Rees Executive Director, WRHI, Wits Reproductive Health and HIV Institute Ad Hominem Professor, Department of Obstetrics and Gynaecology,
More informationSTI Treatment Guidelines. Teodora Wi. Training Course in Sexual and Reproductive Health Research
Teodora Wi Geneva, 28 August 2017 STI Treatment Guidelines Teodora Wi Training Course in Sexual and Reproductive Health Research 2017 Twitter @HRPresearch 1 STI treatment guidelines Neisseria gonorrhoeae
More informationHow Do You Catch An Infection?
How Do You Catch An Infection? Animals Insects Water People Food Infectious Diseases Considerations for the 21 st Century Viruses, bacteria, fungi, protozoa, helminths Infectious diseases are the second
More informationHIV Infection in Pregnancy. Francis J. Ndowa WHO RHR/STI
HIV Infection in Pregnancy Francis J. Ndowa WHO RHR/STI FJN_STI_2005 Department of reproductive health and research Département santé et recherche génésiques Session outline Effect of pregnancy on HIV
More informationSexually Transmitted Infections. Naluce Manuela Morris, MPH, CHES
Sexually Transmitted Infections Naluce Manuela Morris, MPH, CHES Handshake Activity Handshake Activity Mrs. or Mr. X Mrs. or Mr. Y Carry this glove but do not put it on Put this glove on before shaking
More informationSTI s. (Sexually Transmitted Infections)
STI s (Sexually Transmitted Infections) Build Awareness In Canada and around the world, the trend is clear: sexually transmitted infections (STIs) are on the rise. One of the primary defenses in the fight
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationSexual health: Hot topics. Anne Connolly Vice President FSRH
Sexual health: Hot topics Anne Connolly Vice President FSRH To cover Contraception choices Contraception safety Sexual history taking Relevant tests We don t do great. 30 50% pregnancies are unplanned
More informationSexually Transmitted Infections in the Adolescent Population. Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System
Sexually Transmitted Infections in the Adolescent Population Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System STI in the Adolescent High school students nationwide, 34.2% were
More informationSexual and Reproductive Health
Technical Guidance for Round 8 Global Fund HIV Proposals Cross-Cutting Issues Sexual and Reproductive Health Working document - 3 April 2008 Elements concerning the service delivery area to be considered
More informationPopulation Council Strategic Priorities Framework
Population Council Strategic Priorities Framework For 65 years, the Population Council has conducted research and delivered solutions that address critical health and development issues and improve lives
More informationAction Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)
NEWLY DIAGNOSED/ NEW TO CARE PROGRAM SITE: REVIEWER(S): REVIEW DATE: CORE SERVICES Outpatient/Ambulatory Health Services Tool - 2018 (OLD) SECTION 1: CHART REVIEW Review for newly diagnosed HIV patients
More informationContraception for Adolescents: What s New?
Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationII. Adolescent Fertility III. Sexual and Reproductive Health Service Integration
Recommendations for Sexual and Reproductive Health and Rights Indicators for the Post-2015 Sustainable Development Goals Guttmacher Institute June 2015 As part of the post-2015 process to develop recommendations
More informationInterested in working with us?
Interested in working with us? Our patient survey data collection is ongoing ANONYMOUS survey of opioid using women in treatment, ages 18-45. All participants receive $20 for time and effort Survey is
More informationSEX AND SEXUALLY TRANSMITTED INFECTIONS
SEX AND SEXUALLY TRANSMITTED INFECTIONS Sex and STIs Be fully informed, Be safe! Prevent Pregnancy Practice abstinence Use effective birth control Use Emergency Contraception Prevent STI s Practice Abstinence
More informationUpdated Guidelines for Post-Assault Testing and Treatment
Updated Guidelines for Post-Assault Testing and Treatment Ann S. Botash, MD Professor of Pediatrics October 5, 2016!" Disclosure Statement Ann S. Botash, MD, has no financial relationships with any commercial
More informationTRANS-NIH PLAN FOR HIV RELATED RESEARCH
National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office
More informationWhat You Need to Know. Sexually Transmitted Infections (STIs)
What You Need to Know Sexually Transmitted Infections (STIs) What You Need to Know About STIs What are STIs? Sexually transmitted infections (STIs) are diseases that spread through sexual contact. If you
More informationPercentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015
TABLE 1 Percentage of family planning, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and Clinic characteristics 2010 Yes No Focuses on reproductive
More informationUnderstanding the results of CAPRISA 004
A Cascade of Hope and Questions Volume 2 Understanding the results of CAPRISA 004 Key messages CAPRISA 004 provides the first proof of concept that a microbicide (1% tenofovir gel) can reduce women s risk
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More informationSexually Transmitted Infections. Kim Dawson October 2010
Sexually Transmitted Infections Kim Dawson October 2010 Objectives: You will learn about: Sexually Transmitted Infections (STI s). How they are transferred. High risk behavior. The most common STI s. How
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More informationFor questions or comments, please contact:
The Initiative for Multipurpose Prevention Technologies (IMPT) is a product neutral, global collaboration that advances the development of MPTs to address the interlinked risks of unintended pregnancy
More informationWomen s Health in Women s Hands: The Promise of MPTs
2 July 2014 Felicia Stewart Center at UCSF ANSIRH Oakland, California, USA Women s Health in Women s Hands: The Promise of MPTs Special Guests: Manjula Lusti-Narasimhan (WHO) Ina Park (CDPH) Bethany Young
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationInfectious Diseases and Sexual Health in Southwark
Chapter 7 Infectious Diseases and Sexual Health in Southwark Introduction 7.1 The JSNA 2008 did not reflect the problems of infectious diseases and this chapter redresses this gap. Infectious diseases
More informationDiflucan oral. Cari untuk: Cari Cari
Cari untuk: Cari Cari Diflucan oral Diflucan (fluconazole) is used to treat and prevent fungal infections. Includes Diflucan side effects, interactions and indications. 1-3-2018 Diflucan Dosage. Generic
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationVaginitis. Antibiotics Changes in hormone levels due to pregnancy, breastfeeding, or menopause Douching Spermicides Sexual intercourse Infection
WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Vaginitis Vaginitis is an inflammation of a woman s vagina. It is one of the most common reasons why women see their health care providers.
More informationConsultation on the Draft National Strategies for Blood Borne Viruses and Sexually Transmissible Infections
Consultation on the Draft National Strategies for Blood Borne Viruses and Sexually Transmissible Infections AFAO comments on draft Third National Sexually Transmissible Infections Strategy 2014 2017 AFAO
More informationThe HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
More informationKenya. Service Provision Assessment Survey Family Planning Key Findings
Kenya Service Provision Assessment Survey 2004 Family Planning Key Findings This report summarizes the family planning findings of the 2004 Kenya Service Provision Assessment Survey (KSPA), carried out
More informationSTI Review. CALM: STI/HIV - Lesson One (Handout 3) Bacteria/ Transmission. Symptoms. Disease. Virus
STI Review Bacteria/ Virus? Transmission Chlamydia Bacteria Unprotected vaginal or anal sex with a person who has Chlamydia Genital Herpes Virus By direct contact with the sores or blisters of an infected
More informationTrends in STDs among Young People in New York State
Trends in STDs among Young People in New York State Kris Mesler, Bureau of Child and Adolescent Health Alison Muse, Bureau of Sexually Transmitted Disease Control New York State Department of Health Figure
More informationUniversity Health Services at CMU STI Awareness Month specials for students:
University Health Services at CMU STI Awareness Month specials for students: -Free condoms during April (10 per student) -Free walk-in rapid HIV testing April 22-27 (no appointment needed) -STI Screening
More informationSexually Transmitted Diseases This publication was made possible by Grant Number TP1AH from the Department of Health and Human Services,
Sexually Transmitted Diseases This publication was made possible by Grant Number TP1AH000081-01-01 from the Department of Health and Human Services, Office of Adolescent Health; its contents are solely
More informationHIV Prevention for People Living with HIV/AIDS: Indicators for HIV Care and Treatment Settings
HIV Prevention for People Living with HIV/AIDS: Indicators for HIV Care and Treatment Settings Daniel Kidder, PhD Pam Bachanas, PhD Amy Medley, PhD HEATLHQUAL All Country Learning Network (ACLN) Meeting
More informationSexually Transmitted. Diseases
Sexually Transmitted Diseases How can I get an STD? Many STDs are carried and transmitted through semen and vaginal fluids. Some STDs can be spread through skin to skin contact Mother to child STDs: Signs
More informationFertility Management in HIV. INTEREST Workshop, 16 Dakar May 2013 Vivian Black, Director Clinical Programmes Wits Reproductive Health & HIV Institute
Fertility Management in HIV INTEREST Workshop, 16 Dakar May 2013 Vivian Black, Director Clinical Programmes Wits Reproductive Health & HIV Institute What to consider Does HIV affect fertility success?
More information